A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis
1 other identifier
interventional
658
2 countries
33
Brief Summary
A study to assess the safety and effectiveness of tacrolimus cream in the treatment of psoriasis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
33 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 16, 2006
CompletedFirst Posted
Study publicly available on registry
February 20, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2007
CompletedDecember 24, 2007
December 1, 2007
February 16, 2006
December 19, 2007
Conditions
Keywords
Interventions
Eligibility Criteria
You may qualify if:
- Clinical diagnosis of plaque psoriasis
You may not qualify if:
- Skin disorder other than plaque psoriasis in the areas to be treated.
- Disease on only elbows, knees, and scalp
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Astellas Pharma Inclead
- Astellas Pharma US, Inc.collaborator
Study Sites (33)
Unknown Facility
Birmingham, Alabama, 35205, United States
Unknown Facility
Little Rock, Arkansas, 72205, United States
Unknown Facility
San Diego, California, 92123, United States
Unknown Facility
Denver, Colorado, 80246, United States
Unknown Facility
Miami, Florida, 33144, United States
Unknown Facility
West Palm Beach, Florida, 33407, United States
Unknown Facility
Newnan, Georgia, 30263, United States
Unknown Facility
Indianapolis, Indiana, 46256, United States
Unknown Facility
Louisville, Kentucky, 40217, United States
Unknown Facility
North Andover, Massachusetts, 01845, United States
Unknown Facility
Ann Arbor, Michigan, 48109, United States
Unknown Facility
Port Huron, Michigan, 48060, United States
Unknown Facility
St Louis, Missouri, 63110, United States
Unknown Facility
Omaha, Nebraska, 68144, United States
Unknown Facility
New York, New York, 10032, United States
Unknown Facility
Durham, North Carolina, 27710, United States
Unknown Facility
Columbus, Ohio, 43212, United States
Unknown Facility
Dayton, Ohio, 45408, United States
Unknown Facility
Portland, Oregon, United States
Unknown Facility
Knoxville, Tennessee, 37917, United States
Unknown Facility
Dallas, Texas, 75390, United States
Unknown Facility
Houston, Texas, 77058, United States
Unknown Facility
San Antonio, Texas, 78229, United States
Unknown Facility
Salt Lake City, Utah, 84132, United States
Unknown Facility
Norfolk, Virginia, 23507, United States
Unknown Facility
Seattle, Washington, 98101, United States
Unknown Facility
Milwaukee, Wisconsin, 53209, United States
Unknown Facility
Calgary, Alberta, T2S 3B3, Canada
Unknown Facility
Edmonton, Alberta, T5J 3S9, Canada
Unknown Facility
Surrey, British Columbia, V3R, Canada
Unknown Facility
Moncton, New Brunswick, E1C 8X3, Canada
Unknown Facility
Laval, Quebec, H7S 2C6, Canada
Unknown Facility
Montreal, Quebec, H2K 4L5, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
J. Rico, MD
Astellas Pharma US, Inc.
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
February 16, 2006
First Posted
February 20, 2006
Study Completion
January 1, 2007
Last Updated
December 24, 2007
Record last verified: 2007-12